Oncogenicity of L-type amino-acid transporter 1 (LAT1) revealed by targeted gene disruption in chicken DT40 cells

LAT1 is a promising molecular target for human cancer therapy

Mayumi Ohkawa, Yoshiya Ohno, Kazue Masuko, Akiko Takeuchi, Kentaro Suda, Akihiro Kubo, Rieko Kawahara, Shogo Okazaki, Toshiyuki Tanaka, Hideyuki Saya, Masayuki Seki, Takemi Enomoto, Hideki Yagi, Yoshiyuki Hashimoto, Takashi Masuko

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

L-type amino-acid transporter 1 (LAT1) is the first identified light chain of CD98 molecule, disulfide-linked to a heavy chain of CD98. Following cDNA cloning of chicken full-length LAT1, we have constructed targeting vectors for the disruption of chicken LAT1 gene from genomic DNA of chicken LAT1 consisting of 5.4kb. We established five homozygous LAT1-disrupted (LAT1-/-) cell clones, derived from a heterozygous LAT1+/- clone of DT40 chicken B cell line. Reactivity of anti-chicken CD98hc monoclonal antibody (mAb) with LAT1-/- DT40 cells was markedly decreased compared with that of wild-type DT40 cells. All LAT1-/- cells were deficient in L-type amino-acid transporting activity, although alternative-splice variant but not full-length mRNA of LAT1 was detected in these cells. LAT1-/- DT40 clones showed outstandingly slow growth in liquid culture and decreased colony-formation capacity in soft agar compared with wild-type DT40 cells. Cell-cycle analyses indicated that LAT1-/- DT40 clones have prolonged cell-cycle phases compared with wild-type or LAT1+/- DT40 cells. Knockdown of human LAT1 by small interfering RNAs resulted in marked in vitro cell-growth inhibition of human cancer cells, and in vivo tumor growth of HeLa cells in athymic mice was significantly inhibited by anti-human LAT1 mAb. All these results indicate essential roles of LAT1 in the cell proliferation and occurrence of malignant phenotypes and that LAT1 is a promising candidate as a molecular target of human cancer therapy.

Original languageEnglish
Pages (from-to)649-655
Number of pages7
JournalBiochemical and Biophysical Research Communications
Volume406
Issue number4
DOIs
Publication statusPublished - 2011 Mar 25

Fingerprint

Amino Acid Transport Systems
Chickens
Genes
Neoplasms
Therapeutics
Clone Cells
Cells
Cell Cycle
Clone cells
Growth
Monoclonal Antibodies
Cloning
Cell proliferation
Cell growth

Keywords

  • CD98hc
  • CD98lc
  • DT40
  • Gene disruption
  • LAT1
  • SiRNA

ASJC Scopus subject areas

  • Biochemistry
  • Biophysics
  • Cell Biology
  • Molecular Biology

Cite this

Oncogenicity of L-type amino-acid transporter 1 (LAT1) revealed by targeted gene disruption in chicken DT40 cells : LAT1 is a promising molecular target for human cancer therapy. / Ohkawa, Mayumi; Ohno, Yoshiya; Masuko, Kazue; Takeuchi, Akiko; Suda, Kentaro; Kubo, Akihiro; Kawahara, Rieko; Okazaki, Shogo; Tanaka, Toshiyuki; Saya, Hideyuki; Seki, Masayuki; Enomoto, Takemi; Yagi, Hideki; Hashimoto, Yoshiyuki; Masuko, Takashi.

In: Biochemical and Biophysical Research Communications, Vol. 406, No. 4, 25.03.2011, p. 649-655.

Research output: Contribution to journalArticle

Ohkawa, M, Ohno, Y, Masuko, K, Takeuchi, A, Suda, K, Kubo, A, Kawahara, R, Okazaki, S, Tanaka, T, Saya, H, Seki, M, Enomoto, T, Yagi, H, Hashimoto, Y & Masuko, T 2011, 'Oncogenicity of L-type amino-acid transporter 1 (LAT1) revealed by targeted gene disruption in chicken DT40 cells: LAT1 is a promising molecular target for human cancer therapy', Biochemical and Biophysical Research Communications, vol. 406, no. 4, pp. 649-655. https://doi.org/10.1016/j.bbrc.2011.02.135
Ohkawa, Mayumi ; Ohno, Yoshiya ; Masuko, Kazue ; Takeuchi, Akiko ; Suda, Kentaro ; Kubo, Akihiro ; Kawahara, Rieko ; Okazaki, Shogo ; Tanaka, Toshiyuki ; Saya, Hideyuki ; Seki, Masayuki ; Enomoto, Takemi ; Yagi, Hideki ; Hashimoto, Yoshiyuki ; Masuko, Takashi. / Oncogenicity of L-type amino-acid transporter 1 (LAT1) revealed by targeted gene disruption in chicken DT40 cells : LAT1 is a promising molecular target for human cancer therapy. In: Biochemical and Biophysical Research Communications. 2011 ; Vol. 406, No. 4. pp. 649-655.
@article{23a2f3a1f24e4d0d931221c60fab74fc,
title = "Oncogenicity of L-type amino-acid transporter 1 (LAT1) revealed by targeted gene disruption in chicken DT40 cells: LAT1 is a promising molecular target for human cancer therapy",
abstract = "L-type amino-acid transporter 1 (LAT1) is the first identified light chain of CD98 molecule, disulfide-linked to a heavy chain of CD98. Following cDNA cloning of chicken full-length LAT1, we have constructed targeting vectors for the disruption of chicken LAT1 gene from genomic DNA of chicken LAT1 consisting of 5.4kb. We established five homozygous LAT1-disrupted (LAT1-/-) cell clones, derived from a heterozygous LAT1+/- clone of DT40 chicken B cell line. Reactivity of anti-chicken CD98hc monoclonal antibody (mAb) with LAT1-/- DT40 cells was markedly decreased compared with that of wild-type DT40 cells. All LAT1-/- cells were deficient in L-type amino-acid transporting activity, although alternative-splice variant but not full-length mRNA of LAT1 was detected in these cells. LAT1-/- DT40 clones showed outstandingly slow growth in liquid culture and decreased colony-formation capacity in soft agar compared with wild-type DT40 cells. Cell-cycle analyses indicated that LAT1-/- DT40 clones have prolonged cell-cycle phases compared with wild-type or LAT1+/- DT40 cells. Knockdown of human LAT1 by small interfering RNAs resulted in marked in vitro cell-growth inhibition of human cancer cells, and in vivo tumor growth of HeLa cells in athymic mice was significantly inhibited by anti-human LAT1 mAb. All these results indicate essential roles of LAT1 in the cell proliferation and occurrence of malignant phenotypes and that LAT1 is a promising candidate as a molecular target of human cancer therapy.",
keywords = "CD98hc, CD98lc, DT40, Gene disruption, LAT1, SiRNA",
author = "Mayumi Ohkawa and Yoshiya Ohno and Kazue Masuko and Akiko Takeuchi and Kentaro Suda and Akihiro Kubo and Rieko Kawahara and Shogo Okazaki and Toshiyuki Tanaka and Hideyuki Saya and Masayuki Seki and Takemi Enomoto and Hideki Yagi and Yoshiyuki Hashimoto and Takashi Masuko",
year = "2011",
month = "3",
day = "25",
doi = "10.1016/j.bbrc.2011.02.135",
language = "English",
volume = "406",
pages = "649--655",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Academic Press Inc.",
number = "4",

}

TY - JOUR

T1 - Oncogenicity of L-type amino-acid transporter 1 (LAT1) revealed by targeted gene disruption in chicken DT40 cells

T2 - LAT1 is a promising molecular target for human cancer therapy

AU - Ohkawa, Mayumi

AU - Ohno, Yoshiya

AU - Masuko, Kazue

AU - Takeuchi, Akiko

AU - Suda, Kentaro

AU - Kubo, Akihiro

AU - Kawahara, Rieko

AU - Okazaki, Shogo

AU - Tanaka, Toshiyuki

AU - Saya, Hideyuki

AU - Seki, Masayuki

AU - Enomoto, Takemi

AU - Yagi, Hideki

AU - Hashimoto, Yoshiyuki

AU - Masuko, Takashi

PY - 2011/3/25

Y1 - 2011/3/25

N2 - L-type amino-acid transporter 1 (LAT1) is the first identified light chain of CD98 molecule, disulfide-linked to a heavy chain of CD98. Following cDNA cloning of chicken full-length LAT1, we have constructed targeting vectors for the disruption of chicken LAT1 gene from genomic DNA of chicken LAT1 consisting of 5.4kb. We established five homozygous LAT1-disrupted (LAT1-/-) cell clones, derived from a heterozygous LAT1+/- clone of DT40 chicken B cell line. Reactivity of anti-chicken CD98hc monoclonal antibody (mAb) with LAT1-/- DT40 cells was markedly decreased compared with that of wild-type DT40 cells. All LAT1-/- cells were deficient in L-type amino-acid transporting activity, although alternative-splice variant but not full-length mRNA of LAT1 was detected in these cells. LAT1-/- DT40 clones showed outstandingly slow growth in liquid culture and decreased colony-formation capacity in soft agar compared with wild-type DT40 cells. Cell-cycle analyses indicated that LAT1-/- DT40 clones have prolonged cell-cycle phases compared with wild-type or LAT1+/- DT40 cells. Knockdown of human LAT1 by small interfering RNAs resulted in marked in vitro cell-growth inhibition of human cancer cells, and in vivo tumor growth of HeLa cells in athymic mice was significantly inhibited by anti-human LAT1 mAb. All these results indicate essential roles of LAT1 in the cell proliferation and occurrence of malignant phenotypes and that LAT1 is a promising candidate as a molecular target of human cancer therapy.

AB - L-type amino-acid transporter 1 (LAT1) is the first identified light chain of CD98 molecule, disulfide-linked to a heavy chain of CD98. Following cDNA cloning of chicken full-length LAT1, we have constructed targeting vectors for the disruption of chicken LAT1 gene from genomic DNA of chicken LAT1 consisting of 5.4kb. We established five homozygous LAT1-disrupted (LAT1-/-) cell clones, derived from a heterozygous LAT1+/- clone of DT40 chicken B cell line. Reactivity of anti-chicken CD98hc monoclonal antibody (mAb) with LAT1-/- DT40 cells was markedly decreased compared with that of wild-type DT40 cells. All LAT1-/- cells were deficient in L-type amino-acid transporting activity, although alternative-splice variant but not full-length mRNA of LAT1 was detected in these cells. LAT1-/- DT40 clones showed outstandingly slow growth in liquid culture and decreased colony-formation capacity in soft agar compared with wild-type DT40 cells. Cell-cycle analyses indicated that LAT1-/- DT40 clones have prolonged cell-cycle phases compared with wild-type or LAT1+/- DT40 cells. Knockdown of human LAT1 by small interfering RNAs resulted in marked in vitro cell-growth inhibition of human cancer cells, and in vivo tumor growth of HeLa cells in athymic mice was significantly inhibited by anti-human LAT1 mAb. All these results indicate essential roles of LAT1 in the cell proliferation and occurrence of malignant phenotypes and that LAT1 is a promising candidate as a molecular target of human cancer therapy.

KW - CD98hc

KW - CD98lc

KW - DT40

KW - Gene disruption

KW - LAT1

KW - SiRNA

UR - http://www.scopus.com/inward/record.url?scp=79953028951&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953028951&partnerID=8YFLogxK

U2 - 10.1016/j.bbrc.2011.02.135

DO - 10.1016/j.bbrc.2011.02.135

M3 - Article

VL - 406

SP - 649

EP - 655

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 4

ER -